May 18, 2016 — Rational Surgical Solutions announced at the American Urological Association 2016 Annual Meeting (AUA2016) that its mCRPC Master is now available free to doctors, thanks to sponsorship by drug manufacturers. The mCRPC Master is a mobile app that provides current clinical treatment guidelines to help doctors better treat metastatic castrate-resistant prostate cancer.
The app can be downloaded from the Apple Store for iPhones and iPads and from Google Play for Android phones, and the $21.99 yearly subscription fee will be waived.
Healthcare providers enter patient clinical data into the application, which determines and displays the appropriate treatment options, guidelines for maintaining bone health, and recommendations for serum lab testing and imaging studies. Information can be viewed on the device, emailed to the provider or patient for printing, or imported into an electronic health record. No sensitive patient information resides in the application or on the mobile device.
As new developments in the care of mCRPC are reported, the application is updated within days of publication, allowing healthcare providers to provide the most current and comprehensive care for their patients as possible.
For more information: www.rati-fi.com
March 30, 2023 
![A supply problem with Pluvicto [177Lu-vipivotide tetraxetan; Novartis], the radiopharmaceutical used to treat metastatic prostate cancer, has led to shortages resulting in a delay of 3 months or longer for new patients](/sites/default/files/styles/feed_medium/public/Screen%20Shot%202023-03-16%20at%201.46.39%20PM.png?itok=a2-uUeQz)
